Key Points
-
Some genes implicated in systemic lupus erythematosus (SLE) and lupus nephritis might contribute to the pathology of disease by breaching immune tolerance and promoting autoantibody production
-
A subset of SLE and/or lupus nephritis genes might augment innate immune signalling and IFN-I production; other SLE genes might modulate the molecular pathways that lead to renal tissue damage
-
Genes that affect the accessibility and handling of apoptotic material and chromatin might also contribute to SLE and/or lupus nephritis
-
The presence of cognate antigens on the glomerular matrix, together with intrinsic molecular abnormalities in resident renal cells, could further accentuate disease progression in lupus nephritis
-
Differential involvement of the above-listed mechanisms in patients could potentially explain the wide spectrum of clinical phenotypes observed among individuals with SLE and lupus nephritis
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder that has a broad spectrum of effects on the majority of organs, including the kidneys. Approximately 40–70% of patients with SLE will develop lupus nephritis. Renal assault during SLE is initiated by genes that breach immune tolerance and promote autoantibody production. These genes might act in concert with other genetic factors that augment innate immune signalling and IFN-I production, which in turn can generate an influx of effector leucocytes, inflammatory mediators and autoantibodies into end organs, such as the kidneys. The presence of cognate antigens in the glomerular matrix, together with intrinsic molecular abnormalities in resident renal cells, might further accentuate disease progression. This Review discusses the genetic insights and molecular mechanisms for key pathogenic contributors in SLE and lupus nephritis. We have categorized the genes identified in human studies of SLE into one of four pathogenic events that lead to lupus nephritis. We selected these categories on the basis of the cell types in which these genes are expressed, and the emerging paradigms of SLE pathogenesis arising from murine models. Deciphering the molecular basis of SLE and/or lupus nephritis in each patient will help physicians to tailor specific therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 65, 753–763 (2013).
Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929–939 (2008).
Schwartz, N., Goilav, B. & Putterman, C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr. Opin. Rheumatol. 26, 502–509 (2014).
Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).
Sang, A., Zheng, Y. Y. & Morel, L. Contributions of B cells to lupus pathogenesis. Mol. Immunol. 62, 329–338 (2014).
Davidson, A. & Aranow, C. Lupus nephritis: lessons from murine models. Nat. Rev. Rheumatol. 6, 13–20 (2010).
Reddy, V., Jayne, D., Close, D. & Isenberg, D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res. Ther. 15 (Suppl. 1), S2 (2013).
Liu, Y. & Anders, H. J. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin. Pract. (2014).
Okamoto, A. et al. Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice. Kidney Int. 82, 969–979 (2012).
Zhang, Z., Kyttaris, V. C. & Tsokos, G. C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183, 3160–3169 (2009).
Miyake, K., Akahoshi, M. & Nakashima, H. Th subset balance in lupus nephritis. J. Biomed. Biotechnol. 2011, 980286 (2011).
Aringer, M., Gunther, C. & Lee-Kirsch, M. A. Innate immune processes in lupus erythematosus. Clin. Immunol. 147, 216–222 (2013).
Lech, M. & Anders, H. J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 24, 1357–1366 (2013).
Kiefer, K., Oropallo, M. A., Cancro, M. P. & Marshak-Rothstein, A. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell Biol. 90, 498–504 (2012).
Bagavant, H. & Fu, S. M. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 21, 489–494 (2009).
Nowling, T. K. & Gilkeson, G. S. Mechanisms of tissue injury in lupus nephritis. Arthritis Res. Ther. 13, 250 (2011).
Guerra, S. G., Vyse, T. J. & Cunninghame Graham, D. S. The genetics of lupus: a functional perspective. Arthritis Res. Ther. 14, 211 (2012).
Flesher, D. L., Sun, X., Behrens, T. W., Graham, R. R. & Criswell, L. A. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev. Clin. Immunol. 6, 461–479 (2010).
Crispin, J. C., Hedrich, C. M. & Tsokos, G. C. Gene-function studies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 9, 476–484 (2013).
Deng, Y. & Tsao, B. P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 6, 683–692 (2010).
Graham, R. R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40, 1059–1061 (2008).
Guo, Y., Orme, J. & Mohan, C. A genopedia of lupus genes - lessons from gene knockouts. Curr. Rheumatol. Rev. 9, 90–99 (2013).
Niewold, T. B. et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 71, 463–468 (2012).
Jensen, M. A. et al. Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients. Ann. Rheum. Dis. 72, 596–601 (2013).
Richez, C. et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB−/−Yaa and FcgammaRIIB−/− mouse models of systemic lupus erythematosus. J. Immunol. 184, 796–806 (2010).
Qin, L. et al. Association of IRF5 gene polymorphisms and lupus nephritis in a Chinese population. Nephrology (Carlton) 15, 710–713 (2010).
Morel, L. et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl Acad. Sci. USA 97, 6670–6675 (2000).
Mohan, C. et al. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J. Immunol. 162, 6492–6502 (1999).
Xie, S. & Mohan, C. Divide and conquer—the power of congenic strains. Clin. Immunol. 110, 109–111 (2004).
Henry, T. & Mohan, C. Systemic lupus erythematosus—recent clues from congenic strains. Arch. Immunol. Ther. Exp. (Warsz.) 53, 207–212 (2005).
Mohan, C. et al. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J. Clin. Invest. 103, 1685–1695 (1999).
Morel, L. et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J. Immunol. 158, 6019–6028 (1997).
Vaughn, S. E. et al. Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J. Leukoc. Biol. 92, 577–591 (2012).
Avalos, A. M., Meyer-Wentrup, F. & Ploegh, H. L. B-cell receptor signaling in lymphoid malignancies and autoimmunity. Adv. Immunol. 123, 1–49 (2014).
Shao, W. H. & Cohen, P. L. The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets. Expert Rev. Clin. Immunol. 10, 573–582 (2014).
Castillejo-Lopez, C. et al. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann. Rheum. Dis. 71, 136–142 (2012).
Coughlin, J. J. et al. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J. Immunol. 175, 7179–7184 (2005).
Shao, B. et al. Hyperglycaemia promotes human brain microvascular endothelial cell apoptosis via induction of protein kinase C-βI and prooxidant enzyme NADPH oxidase. Redox Biol. 2, 694–701 (2014).
Liu, L. et al. PKCβII acts downstream of chemoattractant receptors and mTORC2 to regulate cAMP production and myosin II activity in neutrophils. Mol. Biol. Cell 25, 1446–145 (2014).
Zheng, Y. et al. Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells. Blood 105, 3648–3654. (2005).
Roberts, D. M. et al. A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. Mol. Cell Biol. 24, 10515–10528 (2004).
Oleksyn, D. et al. Protein kinase Cβ is required for lupus development in Sle mice. Arthritis Rheum. 65, 1022–1031 (2013).
Yu, C. C., Mamchak, A. A. & DeFranco, A. L. Signaling mutations and autoimmunity. Curr. Dir. Autoimmun. 6, 61–88 (2003).
Lamagna, C. et al. B cell-specific loss of Lyn kinase leads to autoimmunity. J. Immunol. 192, 919–928 (2014).
Hua, Z. et al. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J. Immunol. 192, 875–885 (2014).
Yu, C. C., Yen, T. S., Lowell, C. A. & DeFranco, A. L. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr. Biol. 11, 34–38 (2001).
Samuelson, E. M. et al. Blk haploinsufficiency impairs the development, but enhances the functional responses, of MZ B cells. Immunol. Cell Biol. 90, 620–629 (2012).
Samuelson, E. M. et al. Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice. PLoS ONE 9, e92054 (2014).
Hata, A. et al. Functional analysis of Csk in signal transduction through the B-cell antigen receptor. Mol. Cell Biol. 14, 7306–7313 (1994).
Manjarrez-Orduno, N. et al. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet. 44, 1227–1230 (2012).
Dai, X. et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 123, 2024–2036 (2013).
Bayley, R. et al. The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-204796.
Zhang, J. et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 43, 902–907 (2011).
Brownlie, R. J. et al. Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function. Sci. Signal. 5, ra87 (2012).
Ivashkiv, L. B. PTPN22 in autoimmunity: different cell and different way. Immunity 25, 91–93 (2013).
Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 (2002).
Mohan, C., Adams, S., Stanik, V. & Datta, S. K. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177, 1367–1381 (1993).
Barcellos, L. F. et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet. 5, e1000696 (2009).
Graham, R. R. et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 15, 823–830 (2007).
Fernando, M. M. et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 4, e1000024 (2008).
Sharpe, A. H. Mechanisms of costimulation. Immunol. Rev. 229, 5–11 (2009).
Farres, M. N., Al-Zifzaf, D. S., Aly, A. A. & Abd Raboh, N. M. OX40/OX40L in systemic lupus erythematosus: association with disease activity and lupus nephritis. Ann. Saudi Med. 31, 29–34 (2011).
Yang, W. et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am. J. Hum. Genet. 92, 41–51 (2013).
Shah, K. et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res. Ther. 12, R53 (2010).
Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849–1860 (2011).
Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748–755 (2008).
Jacobi, A. M. et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48, 1332–1342 (2003).
Yang, W. et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 6, e1000841 (2010).
Wang, D. et al. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int. Immunol. 17, 1179–1191 (2005).
Kim, S. J. et al. Tolerogenic function of Blimp-1 in dendritic cells. J. Exp. Med. 208, 2193–2199 (2011).
Zhou, Z. et al. Blimp-1 siRNA inhibits B cell differentiation and prevents the development of lupus in mice. Hum. Immunol. 74, 297–301 (2013).
Amarilyo, G., Lourenco, E. V., Shi, F. D. & La Cava, A. IL-17 promotes murine lupus. J. Immunol. 193, 540–543 (2014).
Schmidt, T. et al. Function of the Th17/interleukin-17A immune response in murine lupus nephritis. Arthritis Rheumatol. 67, 475–487 (2015).
Tan, W. et al. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 63, 2755–2763 (2011).
Lashine, Y. A., Salah, S., Aboelenein, H. R. & Abdelaziz, A. I. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus 24, 240–247 (2014).
Crispin, J. C. et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J. Immunol. 188, 3567–3571 (2012).
Apostolidis, S. A. et al. Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J. Biol. Chem. 288, 26775–26784 (2013).
Richman, I. B. et al. European genetic ancestry is associated with a decreased risk of lupus nephritis. Arthritis Rheum. 64, 3374–3382 (2012).
Taylor, K. E. et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7, e1001311 (2011).
Taylor, K. E. et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 4, e1000084 (2008).
Jacob, C. O. et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J. Immunol. 171, 1564–1571 (2003).
Rajabi, P., Alaee, M., Mousavizadeh, K. & Samadikuchaksaraei, A. Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis. Inflamm. Res. 61, 1347–1354 (2012).
Zhou, X. J. et al. A replication study from Chinese supports association between lupus-risk allele in TNFSF4 and renal disorder. Biomed. Res. Int. 2013, 597921 (2013).
Sanchez, E. et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1752–1757 (2011).
Obermoser, G. & Pascual, V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 19, 1012–1019 (2010).
Fairhurst, A. M. et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J. Immunol. 183, 6831–6838 (2009).
Triantafyllopoulou, A. et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc. Natl Acad. Sci. USA 107, 3012–3017 (2010).
He, C. F. et al. TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population. Lupus 19, 1181–1186 (2010).
Frucht, D. M. et al. STAT4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J. Immunol. 164, 4659–4664 (2000).
Kaplan, M. H. STAT4: a critical regulator of inflammation in vivo. Immunol. Res. 31, 231–242 (2005).
Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218–1222 (2006).
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Elkon, K. B. & Stone, V. V. Type I interferon and systemic lupus erythematosus. J. Interferon Cytokine Res. 31, 803–812 (2011).
Dang, J. et al. Gene-gene interactions of IRF5, STAT4, IKZF1 and ETS1 in systemic lupus erythematosus. Tissue Antigens 83, 401–408 (2014).
Karassa, F. B. et al. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int. 63, 1475–1482 (2003).
Brown, E. E., Edberg, J. C. & Kimberly, R. P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 40, 567–581 (2007).
Floto, R. A. et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11, 1056–1058 (2005).
Breunis, W. B. et al. Copy number variation at the FCGR locus includes FCGR3A, FCGRXXXXX2C and FCGR3B but not FCGR2A and FCGR2B. Hum. Mutat. 30, E640–E650 (2009).
Fanciulli, M. et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 39, 721–723 (2007).
Morris, D. L. et al. Evidence for both copy number and allelic (NA1/NA2) risk at the FCGR3B locus in systemic lupus erythematosus. Eur. J. Hum. Genet. 18, 1027–1031 (2010).
Clynes, R., Dumitru, C. & Ravetch, J. V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279, 1052–1054 (1998).
Bergtold, A. et al. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177, 7287–7295 (2006).
Sánchez-Mejorada, G. & Rosales, C. Signal transduction by immunoglobulin Fc receptors. J. Leukoc. Biol. 63, 521–533 (1998).
Celhar, T., Magalhães, R. & Fairhurst, A. M. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol. Res. 53, 58–77 (2012).
Shrivastav, M. & Niewold, T. B. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front. Immunol. 4, 319 (2013).
Zhou, X. J. et al. Association of TLR9 gene polymorphisms with lupus nephritis in a Chinese Han population. Clin. Exp. Rheumatol. 28, 397–400 (2010).
Jacob, C. O. et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 106, 6256–6261 (2009).
Barrat, F. J. et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582–3586 (2007).
Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417–428 (2006).
Verstrepen, L. et al. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem. Pharmacol. 78, 105–114 (2009).
Lewis, M. J. et al. BE2L3 polymorphism amplifies NF-κB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases. Am. J. Hum. Genet. 96, 221–234 (2015).
Zuo, X. B. et al. Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population. Rheumatol. Int. 34, 459–464 (2014).
Hovelmeyer, N. et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 41, 595–601 (2011).
Caster, D. J. et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J. Am. Soc. Nephrol. 24, 1743–1754 (2013).
Bates, J. S. et al. Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun. 10, 470–477 (2009).
Zhou, Y. et al. Multiple lupus-associated ITGAM variants alter Mac-1 functions on neutrophils. Arthritis Rheum. 65, 2907–2916 (2013).
Fagerholm, S. C. et al. The CD11b-integrin (ITGAM) and systemic lupus erythematosus. Lupus 22, 657–663 (2013).
Ross, G. D. & Ve˘tvicka, V. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol. 92, 181–184 (1993).
Kim-Howard, X. et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann. Rheum. Dis. 69, 1329–1332 (2010).
Yang, W. et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum. Mol. Genet. 18, 2063–2070 (2009).
Orme, J. & Mohan, C. Macrophages and neutrophils in SLE-An online molecular catalog. Autoimmun. Rev. 11, 365–372 (2012).
Crispín, J. C., Hedrich, C. M. & Tsokos, G. C. Gene-function studies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 9, 476–484 (2013).
Seredkina, N. et al. Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol. Med. 19, 161–169 (2013).
Rekvig, O. P. & Van der Vlag, J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin. Immunopathol. 36, 301–311 (2014).
Zhou, T. B. et al. Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and systemic lupus erythematosus/lupus nephritis: a systematic review and metaanalysis. J. Rheumatol. 39, 686–693 (2012).
Chung, S. A. et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 7, e1001323 (2011).
Liu, K. et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J. Clin. Invest. 119, 911–923 (2009).
Ciferska, H. et al. Expression of nucleic acid binding Toll-like receptors in control, lupus and transplanted kidneys--a preliminary pilot study. Lupus 17, 580–585 (2008).
Papadimitraki, E. D. et al. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus 18, 831–835 (2009).
Patole, P. S. et al. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol. Dial. Transplant. 21, 3062–3073 (2006).
Ka, S. M. et al. Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res. Ther. 9, R67 (2007).
Liu, S. et al. TRAF6 knockdown promotes survival and inhibits inflammatory response to lipopolysaccharides in rat primary renal proximal tubule cells. Acta Physiol. (Oxf.) 199, 339–346 (2010).
Benigni, A. et al. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 56, 1569–1578 (2007).
Machida, H. et al. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephrol. Dial. Transplant. 25, 2530–2537 (2010).
Frieri, M. et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J. Nephrol. 25, 1041–1046 (2012).
Lichtnekert, J. et al. Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif. Am. J. Physiol. Renal Physiol. 296, F867–F874 (2009).
Kunter, U. et al. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Kidney Int. 68, 1520–1532 (2005).
Lutz, J. et al. The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J. Mol. Med. (Berl.) 86, 1329–1339 (2008).
da Silva, C. G. et al. Hepatocyte growth factor preferentially activates the anti-inflammatory arm of NF-κB signaling to induce A20 and protect renal proximal tubular epithelial cells from inflammation. J. Cell Physiol. 227, 1382–1390 (2012).
Reiser, J. et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 113, 1390–1397 (2004).
Shimada, M. et al. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway. Nephrol. Dial. Transplant. 27, 81–89 (2012).
Ishimoto, T. et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol. Dial. Transplant. 28, 1439–1446 (2013).
Yu, C. C. et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416–2423 (2013).
Ichinose, K. et al. Cutting edge: calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J. Immunol. 187, 5500–5504 (2011).
Fu, S. M., Deshmukh, U. S. & Gaskin, F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J. Autoimmun. 37, 104–112 (2011).
Ge, Y. et al. Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis. J. Exp. Med. 210, 2387–2401 (2013).
Dai, C. et al. Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage. Curr. Opin. Immunol. 31, 87–96 (2014).
Guo, Y., Orme, J. & Mohan, C. A genopedia of lupus genes - lessons from gene knockouts. Curr. Rheumatol. Rev. 9, 90–99 (2013).
Shao, W. H. & Cohen, P. L. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res. Ther. 13, 202 (2011).
Pieterse, E. & Van der Vlag, J. Breaking immunological tolerance in systemic lupus erythematosus. Front. Immunol. 5, 164 (2014).
Hartleben, B. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120, 1084–1096 (2010).
Yaniv, G. et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun. Rev. 14, 75–79 (2015).
Mehra, S. & Fritzler, M. J. The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease. J. Immunol. Res. 2014, 368274 (2014).
Gatto, M. et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun. Rev. 12, 523–536 (2013).
Rekvig, O. P. & Van der Vlag, J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin. Immunopathol. 36, 301–311 (2014).
Munoz, L. E. et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280–289 (2010).
Cohen, P. L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196, 135–140 (2002).
Rodriguez-Manzanet, R. et al. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc. Natl Acad. Sci. USA 107, 8706–8711 (2010).
Knight, J. S. & Kaplan, M. J. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 24, 441–450 (2012).
Magna, M. & Pisetsky, D. S. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol. Med. 20, 138–146 (2014).
Cunninghame Graham, D. S., Akil, M. & Vyse, T. J. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) 46, 927–930 (2007).
Mevorach, D. Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis 15, 1114–1123 (2010).
Leffler, J., Bengtsson, A. A. & Blom, A. M. The complement system in systemic lupus erythematosus: an update. Ann. Rheum. Dis. 73, 1601–1606 (2014).
Saxena, R., Mahajan, T. & Mohan, C. Lupus nephritis: current update. Arthritis Res. Ther. 13, 240 (2011).
Liu, Y. & Anders, H. J. Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin. Pract. 128, 224–231 (2014).
Liu, Z. & Davidson, A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat. Med. 18, 871–882 (2012).
Putterman, C. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun. Rev. 2, 7–11 (2004).
Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat. Genet. 40, 211–216 (2008).
Yang, W. et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 6, e1000841 (2010).
Sanchez, E. et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 63, 3493–3501 (2011).
Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358, 900–909 (2008).
Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234–1237 (2009).
Guthridge, J. M. et al. Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am. J. Hum. Genet. 94, 586–598 (2014).
Okada, Y. et al. A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet. 8, e1002455 (2012).
Lee, H. S. et al. Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. Ann. Rheum. Dis. 73, 1240–1245 (2014).
Liu, P. et al. IL-10 gene polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. PLoS One 8, e69547 (2013).
Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228–1233 (2009).
Lu, R. et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 10, 397–403 (2009).
Zhou, X. J. et al. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann. Rheum. Dis. 70, 1330–1337 (2011).
Sheng, Y. J. et al. Follow-up study identifies two novel susceptibility loci PRKCB and 8p11.21 for systemic lupus erythematosus. Rheumatology (Oxford) 50, 682–688 (2011).
Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005).
Arechiga, A. F. et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J. Immunol. 182, 3343–3347 (2009).
Menard, L. et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635–44 (2011).
Wang, C. et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur. J. Hum. Genet. 21, 994–999 (2013).
Namjou, B. et al. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 60, 1085–1095 (2009).
Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204–210 (2008).
Manku, H. et al. Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet. 9, e1003554 (2013).
Molineros, J. E. et al. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet. 9, e1003222 (2013).
Cunninghame Graham, D. S. et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 7, e1002341 (2011).
Westra, H. J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
Kaufman, K. M. et al. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann. Rheum. Dis. 72, 437–444 (2013).
Koelsch, K. A. et al. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J. Autoimmun. 41, 168–174 (2013).
Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38, 550–555 (2006).
Graham, R. R. et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl Acad. Sci. USA 104, 6758–6763 (2007).
Sigurdsson, S. et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum. Mol. Genet. 17, 872–881 (2008).
Lofgren, S. E. et al. Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells. J. Rheumatol. 37, 574–578 (2010).
Fu, Q. et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 63, 749–754 (2011).
Salloum, R. et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 62, 553–561 (2010).
Baccala, R. et al. Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus. Proc. Natl Acad. Sci. USA 110, 2940–2945 (2013).
Lessard, C. J. et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 90, 648–660 (2012).
Shen, N. et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107, 15838–15843 (2010).
Deng, Y. et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 9, e1003336 (2013).
Zhang, J. et al. Association study of TLR-9 polymorphisms and systemic lupus erythematosus in northern Chinese Han population. Gene 533, 385–388 (2014).
Wang, S. et al. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet. 9, e1003750 (2013).
Agik, S. et al. The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes. J. Rheumatol. 39, 73–8 (2012).
Wang, S. et al. A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun. 13, 380–387 (2012).
Shin, H. D. et al. Common DNase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum. Mol. Genet. 13, 2343–2350 (2004).
Han, S. et al. Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Hum. Mol. Genet. 18, 1171–1180 (2009).
Rhodes, B. et al. The rs1143679 (R77H) lupus associated variant of ITGAM (CD11b) impairs complement receptor 3 mediated functions in human monocytes. Ann. Rheum. Dis. 71, 2028–2034 (2012).
Fossati-Jimack, L. et al. Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells. PLoS One 8, e57082 (2013).
Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270–279 (2011).
Acknowledgements
The authors would like to acknowledge the editorial assistance of Simanta Pathak, University of Houston, USA. Relevant studies in Dr. Putterman's laboratory were supported by grants from the NIH, DK090319 and AR048692. Dr. Putterman is currently a Weston Visiting Professor at the Weizmann Institute.
Author information
Authors and Affiliations
Contributions
Both authors researched the data for the article, provided substantial contributions to discussions of its content, wrote the article, and undertook review and/or editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mohan, C., Putterman, C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 11, 329–341 (2015). https://doi.org/10.1038/nrneph.2015.33
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.33